Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of alpha-1 antitrypsin deficiency disease (AATD)
3.2.1.2 Advancements in biotechnology
3.2.1.3 Approval of novel therapies for AATD
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Adverse effects associated with treatment
3.3 Regulatory landscape
3.4 Pipeline analysis
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021–2032 ($ Mn)
5.1 Key trends
5.2 Medication
5.2.1 Alpha-1 proteinase inhibitor
5.2.2 Bronchodilators
5.2.3 Corticosteroids
5.2.4 Other medications
5.3 Therapy
5.3.1 Augmentation therapy
5.3.2 Oxygen therapy
5.3.3 Other therapies
5.4 Surgery
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021–2032 ($ Mn)
6.1 Key trends
6.2 Parenteral
6.3 Intranasal
6.4 Oral
Chapter 7 Market Estimates and Forecast, By Age Group, 2021–2032 ($ Mn)
7.1 Key trends
7.2 Pediatric
7.3 Adult
Chapter 8 Market Estimates and Forecast, By End-use, 2021–2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Arrowhead Pharmaceuticals, Inc.
10.2 CHIESI Farmaceutici S.p.A.
10.3 CSL Behring
10.4 Epicrispr Biotechnologies, Inc.
10.5 GlaxoSmithKline plc
10.6 Grifols S.A.
10.7 Intellia Therapeutics, Inc.
10.8 Kamada Pharmaceuticals
10.9 Mayo Foundation for Medical Education and Research.
10.10 National Jewish Health
10.11 Shire plc (Takeda Pharmaceutical Company Limited)
10.12 The General Hospital Corporation
10.13 The Johns Hopkins Hospital
